367 related articles for article (PubMed ID: 24015822)
1. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
[TBL] [Abstract][Full Text] [Related]
2. Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.
Bodhankar S; Chen Y; Lapato A; Vandenbark AA; Murphy SJ; Offner H
Front Cell Neurosci; 2014; 8():228. PubMed ID: 25157219
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.
Bodhankar S; Chen Y; Lapato A; Dotson AL; Wang J; Vandenbark AA; Saugstad JA; Offner H
Stroke; 2015 Oct; 46(10):2926-34. PubMed ID: 26306753
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke.
Ren X; Akiyoshi K; Vandenbark AA; Hurn PD; Offner H
Stroke; 2011 Sep; 42(9):2578-83. PubMed ID: 21737801
[TBL] [Abstract][Full Text] [Related]
5. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
6. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
7. Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4
de Freitas E Silva R; Gálvez RI; Pereira VRA; de Brito MEF; Choy SL; Lotter H; Bosurgi L; Jacobs T
Front Immunol; 2020; 11():574491. PubMed ID: 33193363
[TBL] [Abstract][Full Text] [Related]
8. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
9. Reactive glia promote development of CD103
Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
11. Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke.
Li P; Mao L; Liu X; Gan Y; Zheng J; Thomson AW; Gao Y; Chen J; Hu X
Stroke; 2014 Mar; 45(3):857-64. PubMed ID: 24496394
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 is required for estrogen-induced protection against severe EAE in IL-10 deficient mice
Offner H; Lockwood D; Meza-Romero R; Vandenbark AA
Metab Brain Dis; 2023 Feb; 38(2):589-599. PubMed ID: 36454506
[TBL] [Abstract][Full Text] [Related]
13. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 (Programmed Death Ligand 1) Protects Against Experimental Intracerebral Hemorrhage-Induced Brain Injury.
Han R; Luo J; Shi Y; Yao Y; Hao J
Stroke; 2017 Aug; 48(8):2255-2262. PubMed ID: 28706113
[TBL] [Abstract][Full Text] [Related]
15. The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis.
Neumann K; Ostmann A; Breda PC; Ochel A; Tacke F; Paust HJ; Panzer U; Tiegs G
Sci Rep; 2019 Feb; 9(1):2038. PubMed ID: 30765734
[TBL] [Abstract][Full Text] [Related]
16. Regulatory CD8(+)CD122 (+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells.
Bodhankar S; Chen Y; Lapato A; Vandenbark AA; Murphy SJ; Saugstad JA; Offner H
Metab Brain Dis; 2015 Aug; 30(4):911-924. PubMed ID: 25537181
[TBL] [Abstract][Full Text] [Related]
17. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
18. Soluble PD-L1 reprograms blood monocytes to prevent cerebral edema and facilitate recovery after ischemic stroke.
Kim JE; Lee RP; Yazigi E; Atta L; Feghali J; Pant A; Jain A; Levitan I; Kim E; Patel K; Kannapadi N; Shah P; Bibic A; Hou Z; Caplan JM; Gonzalez LF; Huang J; Xu R; Fan J; Tyler B; Brem H; Boussiotis VA; Jantzie L; Robinson S; Koehler RC; Lim M; Tamargo RJ; Jackson CM
Brain Behav Immun; 2024 Feb; 116():160-174. PubMed ID: 38070624
[TBL] [Abstract][Full Text] [Related]
19. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
20. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
